| |
| | 40 CFR PART 302--DESIGNATION, REPORTABLE QUANTITIES, AND NOTIFICATION |
 | | D 5000 (2270) 2H-1-Benzopyran-2-one, 4-hydroxy-3-(3- 81812 Warfarin, and salts, when 1* 4 P001 B 100 (45.4) oxo-1-phenyl-butyl)-, and salts, when present at concentrations present at concentrations greater greater than 0.3%. |
 | | 1 1,2,4 P037 X 1 (0.454) b]oxirene, 3,4,5,6,9,9-hexachloro- 1a,2,2a,3,6,6a,7,7a-octahydro-, (1aalpha,2beta,2aalpha,3beta,6beta, 6aalpha,7beta,7aalpha)-2,7:3,6- 72208 Endrin 1 1,2,4 P051 X 1 (0.454) Dimethanonaphth[2,3-b]oxirene, Endrin, and metabolites... |
 | | 1* 4 P101 A 10 (4.54) Ethylenebisdithiocarbamic acid, salts 111546 Carbamodithioic acid, 1,2- 1* 4 U114 D 5000 (2270) and esters ethanediylbis, salts and esters. |
| www.blm.gov /nhp/news/regulatory/3100/40CFR302.html (3681 words) |
|